OncoMatch/Clinical Trials/NCT06834373
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Official title: Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Is NCT06834373 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Chimeric Antigen Receptor T-Cell Therapy and Rituximab for large b-cell lymphoma with irf4 rearrangement.
Treatment: Chimeric Antigen Receptor T-Cell Therapy · Golcadomide · Rituximab — This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Patients that are able to receive CAR T-cell therapy have a potential for cure, however, many will not be qualified to receive therapy due to relapse. Bridging therapy is therapy intended to transition a patient from one therapy or medication to another or maintain their health or status until they are a candidate for a therapy or have decided on a therapy. Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide and rituximab as bridging therapy before CAR T-cell therapy may kill more tumor cells and may improve the chance of proceeding to CAR T-cell therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
relapsed, progressive and/or refractory disease ... following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted
Lab requirements
Blood counts
Hemoglobin > 7.0 g/dL; ANC ≥ 1000/mcL; Platelet count ≥ 75,000/mcL
Kidney function
Estimated Glomerular function (eGFR) of >= 30 mL/min/1.73m^2 using Cockcroft-Gault, MDRD, or CKD-EPI formula. The same eGFR cutoff applies in case of documented renal involvement by lymphoma
Liver function
Total bilirubin ≤ 1.5 x upper limit of normal (ULN); if total bilirubin is > 1.5 ULN, direct bilirubin must be normal. ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)
Cardiac function
No impaired cardiac function or clinically significant cardiac diseases including, but not limited to: symptomatic congestive heart failure, history of myocardial infarction ≤ 6 months, congestive heart failure requiring ongoing maintenance therapy for life-threatening ventricular arrhythmias, unstable angina pectoris, cardiac arrhythmia
Hemoglobin > 7.0 g/dL; ANC ≥ 1000/mcL; Platelet count ≥ 75,000/mcL; Total bilirubin ≤ 1.5 x ULN; ALT and AST ≤ 2.5 x ULN (≤ 5 x ULN if parenchymal liver involvement); eGFR >= 30 mL/min/1.73m^2; No impaired cardiac function or clinically significant cardiac diseases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
- Mayo Clinic in Florida · Jacksonville, Florida
- Mayo Clinic Health System in Albert Lea · Albert Lea, Minnesota
- Mayo Clinic Health Systems-Mankato · Mankato, Minnesota
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06834373 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify